Celldex Therapeutics reported $23.04M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Amgen USD 8.03B 782M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Celldex Therapeutics USD 23.04M 5.91M Jun/2025
Glaxosmithkline GBP 3.6B 271M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024